EGFR and glioblastoma: While treatment with a TKI targeting EGFR has not shown convincing results in GBM patients, some efficacy was reported for an antibody–drug conjugate comprising depatuximab—an IgG1 mAb—coupled to the tubulin inhibitor monomethyl auristatin F (MMAF)24.